When depression persists despite prior care, it is reasonable to want clear information. Research on psilocybin and treatment-resistant depression is developing. Colorado's regulated natural-medicine pathway is not the same as a clinical trial or proof of efficacy.
Psilocybin therapy for treatment-resistant depression has been studied in controlled research, including a phase 2 trial that measured depression symptoms three weeks after a session. Those findings do not establish a guaranteed benefit, replace standard care, or determine whether someone is eligible for Entheogyn. Eligibility depends on an individualized, physician-reviewed intake that considers health history, medications, psychiatric factors, and safety.
Ask questions about the regulated pathway through a connection call.
To understand what this process can and cannot address, it helps to begin with the meaning of treatment-resistant depression in this specific context.
What treatment-resistant depression means in this context
Treatment-resistant depression is a research and clinical description, not a single universal threshold. Studies may define it by the number of prior treatments that brought insufficient benefit, the severity and duration of the current episode, or other participant criteria. Those definitions are specific to each study and should not be treated as a personal eligibility test.
For example, a small 2025 open-label study enrolled adults with severe treatment-resistant depression who had experienced insufficient benefit from at least five treatments during the current episode. The study included 12 participants and followed them for 12 weeks. That narrow design helps readers understand what researchers examined. But it does not establish that every person with a similar history has the same clinical profile or would receive the same recommendation.
Other research is also defined by its own protocol. A registered phase II study describes treatment-resistant major depression within a randomized, double-blind, active-placebo-controlled design. Its inclusion criteria, screening procedures, and research setting belong to that investigation. A research label therefore does not automatically transfer to a Colorado natural medicine setting.
A diagnosis and a long treatment history can be important information for a medical review, but neither guarantees eligibility at Entheogyn. Colorado services are for adults 21 and older, and Entheogyn conducts individualized screening that considers health history, medications, psychiatric history, and safety factors. The center's physician-reviewed process determines whether proceeding is appropriate. A person should not stop, taper, or change prescribed medication to fit a definition or pursue a session. Medication questions belong with the prescribing clinician and the medical review process.
This article keeps a narrow focus on how treatment-resistant depression appears in research and why those findings require careful interpretation. It is not a replacement for Entheogyn's broader depression guide, which addresses depression-related questions more generally. In either context, research participation criteria, state access, and individual clinical suitability remain separate questions.
What psilocybin therapy for treatment-resistant depression research shows
The strongest evidence comes from controlled research, not from a promise that one approach will work for every person. A phase 2, double-blind randomized trial examined psilocybin among adults with treatment-resistant depression. Participants were assigned to 25 mg, 10 mg, or 1 mg groups. The primary endpoint was the change in Montgomery-Asberg Depression Rating Scale (MADRS) score at week three. Read the phase 2 trial report on PubMed.
At that endpoint, the mean MADRS reduction was 12.0 points in the 25 mg group. 7.9 points in the 10 mg group, and 5.4 points in the 1 mg group. The difference between the 25 mg and 1 mg groups was statistically significant in this study. The 10 mg versus 1 mg comparison was not. These findings describe the participants and conditions in one trial. They do not establish a guaranteed result, determine an individual's candidacy, or demonstrate that the findings transfer directly to a Colorado healing-center setting.
Why the surrounding support matters
Psilocybin research is not simply a comparison of a substance against no care. The phase 2 trial included a structured approach to preparation, support during the experience, and integration afterward. The researchers specifically noted that this was not stand-alone psychotherapy. That distinction matters when interpreting what the study tested: the medicine was provided within a carefully defined clinical container, rather than as an isolated intervention.
A small 2025 open-label study offers additional context, but its scale and design require restraint. It followed 12 adults with severe treatment-resistant depression over 12 weeks. Participants had experienced insufficient benefit from at least five treatments during the current episode. They received one 25 mg dose with pretreatment sessions, support on the dosing day, and three integration sessions. Depressive symptom scores were lower at weeks three and twelve. But an open-label study without a comparison group cannot separate the effects of psilocybin from expectations, therapeutic attention, or other factors. Read the 2025 open-label study on PubMed.
Preparation, skilled support, and integration are therefore central to reading this research responsibly. The experience may be approached as a teacher, while facilitators support the integrity and safety of the container. Integration remains client-led reflection and meaning-making, not a prescribed interpretation. Further research is needed before these findings can answer what will happen for any particular person.
What the evidence cannot tell you yet
| Question | Can show | Cannot establish |
|---|---|---|
| Outcomes | Change under a defined protocol. | What will happen for every person. |
| Eligibility | Who met one study's criteria. | Whether a Colorado service fits you. |
| Support | Results with preparation and integration. | The effect apart from human care. |
Research can clarify what investigators observed in a defined setting. It cannot predict what will happen for every person, establish that a Colorado service is appropriate for you, or turn a study result into a personal recommendation.
Safety signals deserve particular attention. In the phase 2 trial, adverse events were common across all dose groups. Among participants in the 25 mg group, dosing-day reports included headache in 24% and nausea in 22%, with dizziness and fatigue also reported. The study also recorded serious adverse events after dosing, including suicidal ideation and intentional self-injury. These findings do not establish that harm will occur for every participant, but they do show why careful screening, preparation, support, and follow-up matter. Read the trial report on PubMed.
The comparison itself has limits. The phase 2 study did not include an active comparator, so its results cannot answer every question about how this approach compares with another active intervention. The authors also noted limited ethnic diversity in the participant sample and excluded people judged to be at clinically significant risk for suicide. Those boundaries make it harder to generalize the findings across all communities and clinical circumstances.
A 2025 study adds context, not certainty. It followed 12 adults with severe treatment-resistant depression in a 12-week, open-label design. Participants received one 25 mg dose, with preparation, support, and integration sessions. Depressive symptom scores were lower at weeks three and twelve. But a small open-label study has no blinded comparator and can be influenced by expectations, selection, and the surrounding therapeutic structure. Its authors said further research is warranted, rather than presenting the findings as a final answer. Review the open-label study.
That structure matters. The research examined a supported model, not a medicine separated from human care. Preparation and integration are part of the context, as described in this guide to the preparation and integration process. Even so, research support is not a service guarantee. It does not promise eligibility, a particular experience, symptom change, or a specific result for an individual.
How Colorado eligibility differs from clinical-trial eligibility
Colorado's natural medicine framework and a clinical trial answer different questions. For regulated access, an adult must be at least 21 and receive services through a state-licensed healing center. Colorado defines a healing center as a licensed facility where a facilitator can provide and supervise natural medicine services for a participant. Colorado's regulated natural medicine pathway provides more detail on that state framework.
Colorado also divides regulatory responsibility between two agencies. The Department of Revenue (DOR) licenses and regulates natural medicine businesses, including healing centers, cultivation, manufacturing, and testing businesses. The Department of Regulatory Agencies (DORA) licenses and regulates natural medicine facilitators. These roles help explain who oversees the setting and who oversees the professional facilitating the experience.
Legal access is not the same as clinical suitability
Meeting the state age requirement does not establish that a person is clinically suitable for a session. Entheogyn's intake reviews health history, current medications, and mental health background. Its team also considers potential contraindications and reviews each intake individually. A diagnosis is not required to apply, but an application is not a promise of acceptance or a substitute for individualized safety review.
State regulation also does not mean that the service is federally authorized or that regulation proves efficacy. Colorado's state framework exists alongside federal Schedule I status. A regulated setting may provide a defined legal and safety structure within Colorado without establishing that an approach is proven for treatment-resistant depression or appropriate for every person.
Research inclusion is narrower and study-specific
A clinical trial can set its own inclusion and exclusion criteria for a particular research question. Those criteria may involve a documented diagnosis, prior treatment history, age range, medication status, symptom severity, psychiatric history, and other safety factors. Someone may meet Colorado's legal age and access requirements but not qualify for a study. Conversely, research eligibility does not automatically translate into eligibility at a Colorado healing center.
It helps to keep three categories separate: legal access under Colorado's state framework, clinical suitability after individualized review, and research inclusion under a specific protocol. Confusing them can create expectations that neither the research nor the service pathway supports.
What screening involves before a Colorado session
Screening is a careful clinical review, not a formality and not a promise that a session will be appropriate. Entheogyn describes the process as an individualized safety decision for adults 21 and older. A diagnosis of treatment-resistant depression, by itself, does not establish candidacy. The review considers the whole person, current circumstances, and potential risks before anything is scheduled.
- Complete a medical intake. You will share relevant health history, mental health background, current medications, and personal or family history. Be as complete and direct as possible, including information that may feel difficult to discuss. The goal is to give the reviewing team enough context to assess whether this pathway can be considered safely.
- Receive physician review. Every prospective client completes a medical intake reviewed by Entheogyn's on-site physician before medicine is administered. The physician review helps distinguish general interest from an individualized clinical decision. No session is scheduled until the team is satisfied that it is safe to proceed. Physician support and medical oversight are part of the broader safety framework described by Entheogyn.
- Review health and medication history. The team considers current conditions, prescribed medications, medication interactions, and relevant psychiatric history. Entheogyn identifies factors such as a personal or family history of psychosis or mania, and lithium treatment, as matters that may affect eligibility or timing. This is not a complete independent medical checklist, so disclose all relevant details rather than trying to screen yourself.
- Address current antidepressants with your prescriber. Entheogyn states that people currently taking antidepressants, including SSRIs and SNRIs, are not candidates at this time. Do not stop, taper, or change an antidepressant or any other medication based on this article. Medication decisions belong with the prescribing physician. If you are considering a change, speak with that physician and remain in communication with Entheogyn as your situation evolves.
- Discuss current safety concerns. Entheogyn states that people currently experiencing suicidality are not candidates for its sessions. If you are experiencing suicidal thoughts or feel at immediate risk, contact emergency services or a crisis resource now, and reach out to your treating mental health professional. A future screening conversation is not a substitute for immediate support.
- Receive an individualized decision. After the available information is reviewed, the team determines whether proceeding can be considered safely and, when relevant, whether timing or additional discussion is needed. Screening may conclude that a session should not proceed. That boundary is part of responsible care, not a judgment about the seriousness of your experience.
Bring questions about diagnosis, medication, and safety to the professionals responsible for your care. The screening conversation can then remain focused, honest, and grounded in your actual circumstances.
How preparation, the journey, and integration fit together
At Entheogyn, the experience is held as a three-phase process: preparation, the journey, and integration. Each phase has a distinct purpose, so the journey is not treated as an isolated appointment. The process is designed to create room for informed participation, careful support, and reflection before and after the medicine experience.
Preparation creates a foundation
Preparation sessions happen in the days or weeks before the journey. This time allows you and your facilitator to build a genuine working relationship and discuss your intentions, personal history, hopes, and concerns. It is also a chance to ask direct questions about the setting, the process, and anything that may affect your sense of readiness.
Preparation does not require you to arrive with a fixed interpretation or a prescribed objective. Your perspective matters. The facilitator's role is to listen carefully, clarify the process, and help establish conditions in which you can remain informed and engaged.
Support during the journey
During the journey, you retain your autonomy. Facilitators do not direct the experience or interpret what arises for you. Their role is to support safety and the integrity of the setting, while allowing the experience to unfold without imposing a storyline or expected result. This distinction matters: support can be steady and attentive without replacing your own agency.
You can read more about Entheogyn's psilocybin therapy process before deciding what questions you want answered.
Integration continues the work of reflection
Integration is a distinct part of the process, not an optional afterthought. It provides grounded space to reflect on what you experienced and consider what meaning, if any, it holds for you. Reflection remains client-led. No specific emotional response or personal outcome is promised, and integration is not a substitute for individualized medical or mental health care.
Entheogyn also describes medical support as part of its safety structure. A qualified medical professional may be present on site during a journey, and a licensed physician can be on call and reachable throughout every session. Learn more about medical support during the process.
Ask questions about Entheogyn's process on a connection call
Frequently Asked Questions
Does research show that psilocybin can help with treatment-resistant depression?
Research is promising but not conclusive. A phase 2 randomized trial found a greater reduction in depression scores three weeks after a 25 mg group than after a 1 mg group. But the study had important limitations and did not establish a guaranteed result for an individual. Read the trial report.
Does a diagnosis of treatment-resistant depression establish eligibility in Colorado?
No. Colorado-regulated services are for adults 21 and older, and a diagnosis alone does not establish clinical suitability. Entheogyn requires an individualized medical intake and physician review, including medication, psychiatric, and family history, before a session can be scheduled.
Can a doctor prescribe psilocybin in Colorado?
Colorado's regulated natural-medicine pathway is distinct from a conventional prescription. Services occur through licensed healing centers under state rules, while federal status remains separate. Entheogyn's process includes medical screening, but it is not a substitute for ongoing care from your prescribing clinician.
What if I currently have an antidepressant prescription?
Do not stop, taper, or change medication to seek eligibility. Entheogyn's screening guidance says people with current or recently discontinued antidepressant treatment, including SSRIs and SNRIs, are not candidates at this time. Discuss any medication question with the prescribing clinician, then share accurate information during medical review.
What should I expect after screening?
If the review finds the pathway appropriate, preparation comes before the journey, followed by integration. Preparation can include discussing intentions, concerns, and the setting. Integration is client-led reflection, with facilitators supporting the container rather than telling you what an experience means.
Ready to explore the next step?
A connection call can help you review Entheogyn's Colorado process, discuss your questions, and understand whether an individual screening conversation makes sense for you. Research does not promise a particular result, and a call does not establish eligibility. Schedule a connection call to learn more.